Influence of Socioeconomic and Environmental Factors on the Natural History of Idiopathic Pulmonary Fibrosis

Study Purpose

Idiopathic Pulmonary Fibrosis(IPF) is the most common idiopathic interstitial lung disease whose cause is unknown. With age and gender, socio-economic factors are the most influential indicators of health. At present there is very little data on socio-economic factors in the IPF. The investigators hypothesize that a lower socio-economic level and / or exposure to various air pollutants may influence the IPF's natural history, including the severity of diagnosis and prognosis of the IPF. The investigators also hypothesize that the deleterious effect of air pollutants is modulated by individual susceptibility (shorter telomeres) and that this effect is related to oxidative stress and shortening of telomeres.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Man woman over 18 years old.
  • - Certain or probable Idiopathic Pulmonary Fibrosis determined by a multi-disciplinary discussion ("ATS / ERS / JRS / ALAT" 2018 criteria) - Idiopathic Pulmonary Fibrosis with a diagnosis of less than 12 months.
  • - Signed informed consent.
  • - Patient affiliated to a social security scheme or universal health coverage or benefiting from state medical aid.

Exclusion Criteria:

  • - Known cause of Diffuse Interstitial Lung Disease (including connectivity, Hypersensitivity pneumonitis or pneumoconiosis authenticated) - Patient unable to answer questionnaires.
  • - Pregnant or lactating woman.
- Persons under guardianship

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04619199
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

N/A
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Assistance Publique - Hôpitaux de Paris
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Lucile SESE, DrHilario NUNES, PHD
Principal Investigator Affiliation Assistance Publique - Hôpitaux de ParisAssistance Publique - Hôpitaux de Paris
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Recruiting
Countries France
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Idiopathic Pulmonary Fibrosis, Pulmonary Disease, Pulmonary Medicine
Additional Details

Idiopathic Pulmonary Fibrosis is the most common idiopathic interstitial lung disease whose cause is unknown. However, it remains a rare disease, there is an incidence of approximately 4400 new patients per year in France. It is a serious disease with few therapeutic options and a median survival after diagnosis around 36 months. It is also responsible for high morbidity, with a marked deterioration in quality of life (dyspnea, cough, fatigue and anxiodepressive disorders) and significant functional impairment (respiratory failure) With age and gender, socio-economic factors are the most influential indicators of health. At present there is very little data on socio-economic factors in the IPF. The investigators hypothesize that a lower socio-economic level and / or exposure to various air pollutants may influence the IPF's natural history, including the severity of diagnosis and prognosis of the IPF. The investigators also hypothesize that the deleterious effect of air pollutants is modulated by individual susceptibility (shorter telomeres) and that this effect is related to oxidative stress and shortening of telomeres.

Arms & Interventions

Arms

Experimental: Idiopathic Pulmonary Fibrosis

Blood sample were performed during the study for all patients.

Interventions

Diagnostic Test: - Blood sample

Blood sample performed at the inclusion and during the follow-up.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

001 - Service Pneumologie, Bobigny, Avicenne, France

Status

Recruiting

Address

001 - Service Pneumologie

Bobigny, Avicenne,

Bobigny, Avicenne, France

Status

Recruiting

Address

002 - Service Explorations Fonctionnelles Respiratoires

Bobigny, Avicenne,

003 - Service Pneumologie, Paris, Bichat, France

Status

Active, not recruiting

Address

003 - Service Pneumologie

Paris, Bichat,

016 - Service Pneumologie, Caen, CHU Caen Normandie, France

Status

Active, not recruiting

Address

016 - Service Pneumologie

Caen, CHU Caen Normandie,

010 - Service Pneumologie, Dijon, CHU Dijon, France

Status

Active, not recruiting

Address

010 - Service Pneumologie

Dijon, CHU Dijon,

013 - Service Pneumologie, Grenoble, CHU Grenoble, France

Status

Active, not recruiting

Address

013 - Service Pneumologie

Grenoble, CHU Grenoble,

008 - Service Pneumologie, Lille, CHU Lille, France

Status

Active, not recruiting

Address

008 - Service Pneumologie

Lille, CHU Lille,

015 - Service Pneumologie, Montpellier, CHU Montpellier, France

Status

Not yet recruiting

Address

015 - Service Pneumologie

Montpellier, CHU Montpellier,

007 - Service Pneumologie, Rennes, CHU Pontchaillou, France

Status

Recruiting

Address

007 - Service Pneumologie

Rennes, CHU Pontchaillou,

011 - Service Pneumologie, Strasbourg, CHU Strasbourg, France

Status

Active, not recruiting

Address

011 - Service Pneumologie

Strasbourg, CHU Strasbourg,

012 - Service Pneumologie, Tours, CHU Tours, France

Status

Recruiting

Address

012 - Service Pneumologie

Tours, CHU Tours,

014 - Service Pneumologie, Meaux, Ghef, France

Status

Active, not recruiting

Address

014 - Service Pneumologie

Meaux, Ghef,

005 - Service Pneumologie, Paris, Hegp, France

Status

Active, not recruiting

Address

005 - Service Pneumologie

Paris, Hegp,

006 - Service Pneumologie, Lyon, Hospices Civils De Lyon, France

Status

Active, not recruiting

Address

006 - Service Pneumologie

Lyon, Hospices Civils De Lyon,

004 - Service de Pneumologie, Paris, Tenon, France

Status

Recruiting

Address

004 - Service de Pneumologie

Paris, Tenon,

009 - Service Pneumologie, Marseille, France

Status

Not yet recruiting

Address

009 - Service Pneumologie

Marseille, ,

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.